Total trials
144
Active
24
Phase 3
4
Total enrollment
48,100
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ultra-Long GnRH Agonists + Letrozole | — | — | — | — | — | 1 | |
| Ultra-Long GnRH Agonists | — | — | — | — | — | 1 | |
| Clobetasol Patch | — | — | — | — | — | 1 | |
| Clobetasol + Resveratrol Patch | — | — | — | — | — | 1 | |
| Clobetasol in Orabase | — | — | — | — | — | 1 | |
| SGLT2 inhibitor | — | — | — | — | — | 1 |
Next readouts
- 2025-07-15
- 2026-06
- 2027-10-01
Top conditions
- Non-celiac Wheat Sensitivity12
- Non-celiac Gluten Sensitivity6
- Healthy Participants5
- Celiac Disease4
- Endometrial Polyp4
- Endometrial Diseases4
- Healthy4
- Athletes4
Frequently asked questions about University of Palermo
- How many clinical trials does University of Palermo have on ClinicalTrials.gov?
- University of Palermo is listed as the lead sponsor on 144 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Palermo's trials are in Phase 3?
- 4 of University of Palermo's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does University of Palermo focus on?
- University of Palermo's most-studied conditions on ClinicalTrials.gov are Non-celiac Wheat Sensitivity, Non-celiac Gluten Sensitivity, Healthy Participants, Celiac Disease, Endometrial Polyp.
- When are University of Palermo's next clinical trial readouts?
- University of Palermo has 3 upcoming primary-completion readouts tracked here; the soonest is “SGLT-2 Inhibitors in the Treatment of Ascites”, expected around 2025-07-15.